Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression.

calpeptin cholangiocarcinoma cleavage cytoskeleton liver cancer

Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
27 Nov 2023
Historique:
revised: 19 10 2023
received: 05 04 2023
accepted: 12 11 2023
medline: 27 11 2023
pubmed: 27 11 2023
entrez: 27 11 2023
Statut: aheadofprint

Résumé

Intrahepatic cholangiocarcinoma (iCCA) is a primary liver tumour, characterized by poor prognosis and lack of effective therapy. The cytoskeleton protein Filamin A (FLNA) is involved in cancer progression and metastasis, including primary liver cancer. FLNA is cleaved by calpain, producing a 90 kDa fragment (FLNA We evaluated the expression and localization of FLNA and FLNA These findings demonstrate that FLNA is involved in human iCCA progression and calpeptin strongly decreased FLNA

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Intrahepatic cholangiocarcinoma (iCCA) is a primary liver tumour, characterized by poor prognosis and lack of effective therapy. The cytoskeleton protein Filamin A (FLNA) is involved in cancer progression and metastasis, including primary liver cancer. FLNA is cleaved by calpain, producing a 90 kDa fragment (FLNA
METHODS & RESULTS RESULTS
We evaluated the expression and localization of FLNA and FLNA
CONCLUSIONS CONCLUSIONS
These findings demonstrate that FLNA is involved in human iCCA progression and calpeptin strongly decreased FLNA

Identifiants

pubmed: 38010911
doi: 10.1111/liv.15800
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro

Informations de copyright

© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.

Références

Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588.
Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol. 2022;76:1109-1121.
Turgeon MK, Maithel SK. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. Chinese Clin Oncol. 2020;9:4.
Kamarajah S, Giovinazzo F, Roberts KJ, et al. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: review of literature and pooled analysis. Ann Hepato-Biliary-Pancreatic Surg. 2020;24:6-16.
Mcnamara G, Ph D, Zaucha R, Ph D. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. Liv Int. 2022;1:1-11.
Jiang X, Yue J, Lu H, et al. Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci. 2012;9:67-77.
Nakamura F, Stossel TP, Hartwig JH. The filamins: organizers of cell structure and function. Cell Adh Migr. 2011;5:160-169.
Vitali E, Boemi I, Rosso L, et al. FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget. 2017;8:77330-77340.
Donadon M, Di Tommaso L, Soldani C, et al. Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy. Liver Int. 2018;38:303-311.
Chung YS, Jeon Y, Yoo JE, et al. Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma. Hepatol Int. 2023;17:77-85.
Guedj N, Zhan Q, Perigny M, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009;51:93-101.
Van der Flier A, Sonnenberg A. Structural and functional aspects of filamins. Biochim Biophys Acta-Mol Cell Res. 2001;1538:99-117.
Ma HR, Cao L, Wang F, et al. Filamin B extensively regulates transcription and alternative splicing, and is associated with apoptosis in HeLa cells. Oncol Rep. 2020;43:1536-1546.
Bandaru S, Ala C, Zhou A-X, Akyürek LM. Filamin a regulates cardiovascular remodeling. Int J Mol Sci. 2021;22:6555.
Stossel TP, Condeelis J, Cooley L, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol. 2001;2:138-145. doi:10.1038/35052082
Ohta Y, Suzuki N, Nakamura S, Hartwig JH, Stossel TP. The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci USA. 1999;96:2122-2128.
Gorlin JB, Yamin R, Egan S, et al. Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular leaf spring. J Cell Biol. 1990;111:1089-1105.
Salimi R, Bandaru S, Devarakonda S, et al. Blocking the cleavage of filamin a by calpain inhibitor decreases tumor cell growth. Anticancer Res. 2018;38:2079-2085.
Cai L, Li Q, Li W, et al. Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. Int J Clin Oncol. 2020;25:1055-1066. doi:10.1007/s10147-020-01636-7
Savoy RM, Ghosh PM. The dual role of filamin A in cancer: Can't live with (too much of) it, can't live without it. Endocr Relat Cancer. 2013;20:R341-56.
Vitali E, Cambiaghi V, Zerbi A, et al. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23:181-190.
Varamo C, Peraldo-Neia C, Ostano P, et al. Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line resistant to gemcitabine. Cancers (Basel). 2019;11:11.
Oliviero B, Varchetta S, Mele D, et al. MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. Onco Targets Ther. 2022;11:2035919.
Polidoro MA, Ferrari E, Soldani C, et al. Cholangiocarcinoma-on-a-chip: a human 3D platform for personalized medicine. JHEP Rep. 2023;100910. doi:10.1016/j.jhepr.2023.100910
Lauranzano E, Pozzi S, Pasetto L, et al. Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain. 2015;138:974-991.
Dobin A, Davis CA, Schlesinger F, et al. Star: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21. doi:10.1093/bioinformatics/bts635
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-140. doi:10.1093/bioinformatics/btp616
Scherer D, Dávila López MD, Goeppert B, et al. RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling. Cancers (Basel). 2020;12:12.
Copas JB. Regression, prediction and shrinkage. J R Stat Soc Ser B. 1983;45:311-354.
Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;351:h3868.
Zhang K, Zhu T, Gao D, et al. Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patients. J Cancer Res Clin Oncol. 2014;140:1913-1926.
Gao H, Cheng RA, Santos H. Nanoparticle-mediated siRNA delivery systems for cancer therapy. View. 2021;2. doi:10.1002/viw.20200111
Shao QQ, Zhang TP, Zhao WJ, et al. Filamin A: insights into its exact role in cancers. Pathol Oncol Res. 2016;22:245-252.
Krebs K, Ruusmann A, Simonlatser G, Velling T. Expression of FLNa in human melanoma cells regulates the function of integrin α1β1 and phosphorylation and localisation of PKB/AKT/ERK1/2 kinases. Eur J Cell Biol. 2015;94:564-575.
Sun GG, Lu YF, Zhang J, Hu WN. Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. Tumor Biol. 2014;35:3819-3826.
Wieczorek K, Wiktorska M, Sacewicz-Hofman I, et al. Filamin A upregulation correlates with snail-induced epithelial to mesenchymal transition (EMT) and cell adhesion but its inhibition increases the migration of colon adenocarcinoma HT29 cells. Exp Cell Res. 2017;359:163-170.
Bedolla RG, Wang Y, Asuncion A, et al. Nuclear versus cytoplasmic localization of filamin a in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009;15:788-796.
Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011;11:364-374. doi:10.1038/nrc3050
Liu Y, Liu B, Zhang G, qin, Zou J feng, Zou M lin, Cheng Z shun. Calpain inhibition attenuates bleomycin-induced pulmonary fibrosis via switching the development of epithelial-mesenchymal transition. Naunyn Schmiedebergs Arch Pharmacol. 2018;391:695-704. doi:10.1007/s00210-018-1499-z
Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin associates with Smads and regulates transforming growth factor-β signaling. J Biol Chem. 2001;276:17871-17877. doi:10.1074/jbc.M008422200

Auteurs

Eleonora Vitali (E)

Laboratory of Cellular and Molecular Endocrinology, IRCCS Humanitas Research Hospital, Milan, Italy.

Barbara Franceschini (B)

Hepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Milan, Italy.

Flavio Milana (F)

Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Milan, Italy.

Cristiana Soldani (C)

Hepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Milan, Italy.

Michela A Polidoro (MA)

Hepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Milan, Italy.

Roberta Carriero (R)

Bioinformatics Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

Paolo Kunderfranco (P)

Bioinformatics Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

Giampaolo Trivellin (G)

Laboratory of Cellular and Molecular Endocrinology, IRCCS Humanitas Research Hospital, Milan, Italy.

Guido Costa (G)

Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Milan, Italy.

Giulia Milardi (G)

Hepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Milan, Italy.

Luca Di Tommaso (L)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Pathology Department, Humanitas Clinical and Research Center-IRCCS, Milan, Italy.

Guido Torzilli (G)

Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Ana Lleo (A)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.

Andrea G Lania (AG)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

Matteo Donadon (M)

Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Department of General Surgery, University Maggiore Hospital, Novara, Italy.

Classifications MeSH